1. Home
  2. DCTH vs ORGO Comparison

DCTH vs ORGO Comparison

Compare DCTH & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$13.55

Market Cap

372.5M

Sector

Health Care

ML Signal

HOLD

Logo Organogenesis Holdings Inc.

ORGO

Organogenesis Holdings Inc.

HOLD

Current Price

$2.44

Market Cap

299.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCTH
ORGO
Founded
1988
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
372.5M
299.8M
IPO Year
2015
2016

Fundamental Metrics

Financial Performance
Metric
DCTH
ORGO
Price
$13.55
$2.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
2
Target Price
$22.00
$8.50
AVG Volume (30 Days)
573.8K
704.6K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
107.53
1600.00
EPS
N/A
N/A
Revenue
N/A
$564,169,000.00
Revenue This Year
$24.54
N/A
Revenue Next Year
$33.15
$26.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
17.04
52 Week Low
$8.12
$2.04
52 Week High
$13.44
$7.08

Technical Indicators

Market Signals
Indicator
DCTH
ORGO
Relative Strength Index (RSI) 70.39 50.56
Support Level $10.26 $2.26
Resistance Level N/A $2.58
Average True Range (ATR) 0.57 0.11
MACD 0.14 0.00
Stochastic Oscillator 92.89 57.08

Price Performance

Historical Comparison
DCTH
ORGO

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

About ORGO Organogenesis Holdings Inc.

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

Share on Social Networks: